iShares J.P. Morgan $ EM Bond CHF Hedged UCITS ETF (Dist) (0Y3P)

Overview

BioArctic AB (publ) is a pioneering biopharmaceutical company based in Stockholm, Sweden, dedicated to developing novel biological drugs aimed at improving the quality of life for patients suffering from neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Originally established in 2000 under the name BioArctic Neuroscience AB, the company underwent a rebranding in 2016 to its current identity. Throughout its evolution, BioArctic AB has maintained a sharp focus on addressing the unmet medical needs within the realm of neurodegenerative diseases, leveraging its expertise in biotechnology to create impactful treatments. The company fosters a culture of innovation through strategic research collaboration agreements with notable industry partners like Eisai and AbbVie, underscoring its commitment to pioneering advances in medical science.

Products and Services

Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up: These products are at the forefront of BioArctic's advancement against Alzheimer's disease. Lecanemab and its derivatives are engineered to target and modify the disease's progression, promising a potential breakthrough in Alzheimer's treatment.

ABBV-0805: Developed for Parkinson's disease, this treatment exemplifies BioArctic's commitment to expanding its therapeutic reach. ABBV-0805 targets a specific protein associated with Parkinson's, aiming to alleviate symptoms and slow disease progression.

AD-BT2802 and AD-BT2803: These innovative drug projects are designed to combat Alzheimer's disease by enhancing the delivery of antibodies directly into the brain. Utilizing novel blood-brain barrier technology combined with a Brain Transporter system, these therapies aim to improve treatment efficacy by ensuring higher concentrations of therapeutic agents reach the targeted neural tissues.

ND3014 Antibodies: Targeting a broad spectrum of neurodegenerative disorders, the development of ND3014 antibodies represents BioArctic’s venture into addressing various conditions beyond Alzheimer's and Parkinson's diseases. This approach reflects the company's comprehensive strategy to confront neurodegenerative disorders at multiple fronts.

Other Alzheimer's and Parkinson's Disease Treatments: BioArctic's portfolio also includes BAN1503, AD-BT2802, AD-BT2803, AD1502, AD1503, AD2603, ND-BT3814, GD-BT6822, PD1601, BAN0805, PD-BT2238, and PD1602. These cataloged items highlight the company's dedication to offering a diversified arsenal against Alzheimer's and Parkinson's diseases, showcasing a range of therapeutic options intended to meet the varied needs of patients living with these challenging conditions.